Abstract: Abstract:Background:Dexmedetomidine(DEX)is a selective and potent ɑ2adrenergic receptor (ɑ2-AR) agonist.Objective:Summarize the research progress in dexmedetomidine treating ischemia/reperfusionin juryContent:It has also been demonstrated to have protective effects in a variety of .animal models of ischemia/reperfusion (I/R) injury, including the intestine, myocardial, renal, lung, cerebral and liver.DEX modulates gene expression, channel activation, transmitter release, inflammatory processes and apoptotic and necrotic cell death.Trend:The broad spectrum of biological activities associated with DEX continues to expand, and its diverse effects suggest that it may offer a novel therapeutic approach for the treatment of human diseases with I/R involvement.
|